SparX to Present Phase 1 Clinical Updates of SPX-303, a Dual Checkpoint Bispecific Antibody, at Two Events During AACR 2025

CHICAGO, April 18, 2025 /PRNewswire/ -- SparX Biopharmaceutical Corp. announced today that it will present clinical updates on its lead asset, SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody, during the Trial-in-Progress poster session at the 2025 American Association for...